257 related articles for article (PubMed ID: 18158289)
1. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
[TBL] [Abstract][Full Text] [Related]
2. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
4. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
5. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
6. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
Schulz S; Mehilli J; Ndrepepa G; Dotzer F; Dommasch M; Kufner S; Birkmeier KA; Tiroch K; Byrne RA; Schömig A; Kastrati A
Clin Res Cardiol; 2011 Aug; 100(8):691-9. PubMed ID: 21384174
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
8. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
Kandzari DE; Berger PB; Kastrati A; Steinhubl SR; Mehilli J; Dotzer F; Ten Berg JM; Neumann FJ; Bollwein H; Dirschinger J; Schömig A;
J Am Coll Cardiol; 2004 Dec; 44(11):2133-6. PubMed ID: 15582309
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
10. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
[TBL] [Abstract][Full Text] [Related]
11. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
Iijima R; Byrne RA; Ndrepepa G; Braun S; Mehilli J; Berger PB; Schömig A; Kastrati A
Heart; 2009 Feb; 95(2):107-12. PubMed ID: 18801777
[TBL] [Abstract][Full Text] [Related]
12. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Ulm K; Berger PB; Schömig A
Circulation; 2006 Nov; 114(19):2040-6. PubMed ID: 17060377
[TBL] [Abstract][Full Text] [Related]
14. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
16. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials.
Iijima R; Ndrepepa G; Mehilli J; Bruskina O; Schulz S; Schömig A; Kastrati A
Thromb Haemost; 2007 Oct; 98(4):852-7. PubMed ID: 17938811
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
19. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
[TBL] [Abstract][Full Text] [Related]
20. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
